menu
    • menu
    [{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Children's Discovery Institute | Polaris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Neoantigen DNA Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Washington University School of Medicine \/ AstraZeneca | Gateway for Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ AstraZeneca | Gateway for Cancer Research"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"Ovarian carcinoma antigen CA125 (MUC16)","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BostonGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Quest Medical, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cardioplexol","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Washington University School of Medicine \/ Quest Medical, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Quest Medical, Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eisai Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership | Eisai Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"||Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"MacroGenics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Washington University School of Medicine \/ MacroGenics | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ MacroGenics | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co | Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Washington University School of Medicine \/ Merck & Co | Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co | Ipsen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Inapplicable","leadProduct":"89-Zr Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Washington University School of Medicine \/ Molecular Templates","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Molecular Templates"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Washington University School of Medicine \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Genentech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc | Joseph Sanchez Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc | Joseph Sanchez Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Washington University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Institutes of Health | Eisai Inc | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Neurology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Washington University School of Medicine \/ National Institutes of Health | Eisai Inc | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Institutes of Health | Eisai Inc | National Institute on Aging"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Defactinib","moa":"Protein tyrosine kinase 2 beta | Focal adhesion kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Verastem Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Verastem Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Washington University School of Medicine \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Verastem Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Xcovery","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ Xcovery","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Xcovery"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"University of Texas System | Gateway Biotechnology | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ University of Texas System | Gateway Biotechnology | US Department of Defense"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"US Department of Defense | University of Texas System | Gateway Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ US Department of Defense | University of Texas System | Gateway Biotechnology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Servier | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase [NADP] cytoplasmic","graph1":"Hematology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ Servier | Gateway for Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Servier | Gateway for Cancer Research"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Beta-lactam antibiotics","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DSP-0390","moa":"EBP","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ Sumitomo Pharma America","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"HT-ALZ","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | BALCHEM"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | National Institute on Minority Health and Health Disparities","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging | Accelerating Medicines Partnership"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eli Lilly | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Washington University School of Medicine \/ F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ F. Hoffmann-La Roche | Alzheimer's Association | National Institute on Aging"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Remternetug","moa":"Amyloid","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors","highestDevelopmentStatusID":"9","companyTruncated":"Washington University School of Medicine \/ Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech | Institute for Follicular Lymphoma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Washington University School of Medicine \/ Genentech | Institute for Follicular Lymphoma","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Genentech | Institute for Follicular Lymphoma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Washington University School of Medicine \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Novo Nordisk"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx | Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Washington University School of Medicine \/ BioLineRx | Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioLineRx | Biogen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx | Arvrmid Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Washington University School of Medicine \/ BioLineRx | Arvrmid Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioLineRx | Arvrmid Pharma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAd36-SARS-CoV-S","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Ocugen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Measles, Mumps And Rubella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Wugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CIML NK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Washington University School of Medicine \/ Wugen","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Wugen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Celldex Therapeutics | Foundation for Barnes-Jewish Hospital | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CDX-1140","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Celldex Therapeutics | Foundation for Barnes-Jewish Hospital | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Celldex Therapeutics | Foundation for Barnes-Jewish Hospital | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Arcus Biosciences"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | ImmunityBio"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Genentech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Comprehensive Cancer Network | Pfizer Inc | Rapid Novor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elranatamab","moa":"Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Comprehensive Cancer Network | Pfizer Inc | Rapid Novor","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Comprehensive Cancer Network | Pfizer Inc | Rapid Novor"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"SecuraBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ SecuraBio","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ SecuraBio"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Washington University School of Medicine \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Exelixis | Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Good Ventures | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Good Ventures | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Good Ventures | Merck & Co"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co | Joseph Sanchez Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Merck & Co | Joseph Sanchez Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Merck & Co | Joseph Sanchez Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"GlycoMimetics | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ GlycoMimetics | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ GlycoMimetics | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Calithera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"Glutaminase kidney isoform, mitochondrial","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Calithera Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Calithera Biosciences"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"UConn Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ UConn Health","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ UConn Health"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Assertio Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Damon Runyon Cancer Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase [NADP], mitochondrial","graph1":"Hematology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Damon Runyon Cancer Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Damon Runyon Cancer Research Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cue Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Cue Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Cue Biopharma"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Taiho Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Taiho Oncology"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Polaris Group","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Polaris Group"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Apollomics Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APL-101","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Apollomics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Apollomics Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"US Department of Defense | Aclaris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPKAPK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ US Department of Defense | Aclaris Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ US Department of Defense | Aclaris Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Imago BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||Lysine-specific histone demethylase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ AstraZeneca"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NT-I7","moa":"interleukins: interleukin-7 analogues and derivatives; Fc fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ NeoImmuneTech","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ NeoImmuneTech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Sanofi"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Genentech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Wugen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Wugen","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Wugen"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Tilde Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Pyrimethamine","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Tilde Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Tilde Sciences"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Aravive","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Aravive","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Aravive"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bristol Myers Squibb | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Bristol Myers Squibb | Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Bristol Myers Squibb | Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"LB Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LB-102","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Epizyme","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Epizyme"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"SecuraBio | Foundation for Barnes-Jewish Hospital | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ SecuraBio | Foundation for Barnes-Jewish Hospital | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ SecuraBio | Foundation for Barnes-Jewish Hospital | National Cancer Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Curis | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CA-4948","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Curis | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Curis | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"MorphoSys | Foundation for Barnes-Jewish Hospital | Swim Across America | Daniel E. Corbin Jr. Lymphoma Fund","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ MorphoSys | Foundation for Barnes-Jewish Hospital | Swim Across America | Daniel E. Corbin Jr. Lymphoma Fund","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ MorphoSys | Foundation for Barnes-Jewish Hospital | Swim Across America | Daniel E. Corbin Jr. Lymphoma Fund"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Aclaris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPKAPK2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Aclaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Aclaris Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Exelixis"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Revimmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Glycosylated Recombinant Human Interleukin-7","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Revimmune","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Revimmune"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Inapplicable","leadProduct":"18-F FluorApoTrace","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"18-F RO-948","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Aclaris Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ATI-2231","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Aclaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Aclaris Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Cancer Institute | Leidos | UNICO Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Neoantigen Synthetic Long Peptide Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Cancer Institute | Leidos | UNICO Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ National Cancer Institute | Leidos | UNICO Foundation"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Incyte Corporation | PapiVax Biotech | Foundation for Barnes-Jewish Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Personalized Neoantigen Dna Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Incyte Corporation | PapiVax Biotech | Foundation for Barnes-Jewish Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Incyte Corporation | PapiVax Biotech | Foundation for Barnes-Jewish Hospital"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Synthetic Long Peptide Personalized Cancer Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Natera","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Natera"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAd-SARS-CoV-2-S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Washington University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Washington University School of Medicine \/ Bharat Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Bharat Biotech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VSV-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"C-RUSF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Kamuzu University of Health Sciences | Balchem Corp"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"MFGM-RUTF","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Varian Medical Systems","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Varian Medical Systems"}]

    Find Clinical Drug Pipeline Developments & Deals by Washington University School of Medicine

    Menu

    Washington University School of Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 13, 2025

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 14, 2025

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-ALZ

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Hoth, WashU Advance Alzheimer's Program with NK-1 Antagonist HT-ALZ

                            Details : The collaboration aims to advance the clinical development of HT-ALZ, which is being evaluated for the treatment of Alzheimer's disease.

                            Product Name : HT-ALZ

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 02, 2025

                            Lead Product(s) : HT-ALZ

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MFGM-RUTF

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Sponsor : Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : MFGM-RUTF

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Sponsor : Project Peanut Butter | Ministry of Health and Sanitation, Sierra Leone | Arla Foods Ingredients | The Danish Dairy Research Foundation, Denmark

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azeliragon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cantex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblast...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : Azeliragon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cantex Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute | Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 27, 2025

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute | Exelixis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zunsemetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute | Aclaris Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 18, 2024

                            Lead Product(s) : Zunsemetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute | Aclaris Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remternetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 17, 2024

                            Lead Product(s) : Remternetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Alzheimer's Association | Eli Lilly | National Institute on Aging | GHR Foundation | Private Donors

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSP-0390

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sumitomo Pharma America

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Window of Opportunity Study of DSP-0390 in Gliomas

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 10, 2024

                            Lead Product(s) : DSP-0390

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sumitomo Pharma America

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            iPHEX India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BioLineRx | Arvrmid Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Follow...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 09, 2024

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BioLineRx | Arvrmid Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth